AMF Tjanstepension AB Buys 3,206 Shares of Cencora, Inc. $COR

AMF Tjanstepension AB increased its stake in Cencora, Inc. (NYSE:COR) by 2.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 115,849 shares of the company’s stock after buying an additional 3,206 shares during the period. AMF Tjanstepension AB’s holdings in Cencora were worth $36,393,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. purchased a new stake in Cencora in the 4th quarter valued at about $25,000. Oakworth Capital Inc. bought a new stake in shares of Cencora during the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the fourth quarter valued at approximately $27,000. Archer Investment Corp boosted its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $29,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 0.0%

Shares of COR stock opened at $303.31 on Monday. The stock’s fifty day moving average price is $277.22 and its 200 day moving average price is $318.84. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a market cap of $59.01 billion, a price-to-earnings ratio of 23.26, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the firm posted $4.42 EPS. Cencora’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Cencora declared that its Board of Directors has authorized a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have weighed in on COR shares. Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday, May 8th. William Blair initiated coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Wells Fargo & Company lowered their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday, May 11th. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Insider Transactions at Cencora

In related news, Director Lauren M. Tyler purchased 550 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This represents a 14.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.